Viking Therapeutics To Present Data From Phase 2b VOYAGE Study Of VK2809 In Patients With Biopsy-Confirmed NASH/MASH At 75th Liver Meeting 2024

Benzinga05:54

Natera Sees FY24 SG&A $775M-$825M; R&D $375M-$400M' Net Cash Inflows $50M-$75M.

Benzinga05:17

Natera Sees FY24 Revenue $1.61B-$1.64B Vs $1.518B Est

Benzinga05:16

Natera Q3 2024 GAAP EPS $(0.26) Beats $(0.58) Estimate, Sales $439.800M Beat $361.450M Estimate

Benzinga05:13

ARKK's Holdings Ranked by SA Quant Grades

Seeking Alpha03:21

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio

Benzinga02:52